January 28th, 2016, Vancouver, B.C. – Veritas Pharma Inc. (“VRT” or the “Company”) (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) today announced that David Alexander has been appointed as VRT’s Chief Financial Officer. Mr. Alexander will be responsible for leading VRT’s financial strategy and operations, supporting all functions of the organization.

Mr. Alexander is a CPA CA with a BComm with Honors in Finance from the University of British Columbia. Over the past 25 years, in his position as CFO, he has managed the rapid growth of several early stage and startup companies through to exits that total in excess of $1Billion.

As CFO of Arakis Energy Corporation, an international oil and gas development company, he managed its growth from startup to over a billion dollars in assets, moving it from the VSE to the Nasdaq National Market System. Arakis was subsequently sold to Talisman Energy Inc. Previously, Mr. Alexander was CFO of Nortran Pharmaceuticals, Inc., a UBC based pharmaceutical research and development company engaged in the development and commercialization of cardiovascular therapies. While at Nortran, Mr. Alexander helped secure initial and ongoing research financing, and was able to have the firm listed on the VSE. Nortran subsequently, became Cardiome Pharma Corp. (NASDAQ: CRME), a successful Vancouver B.C. based pharmaceutical company

“I am pleased to have David join Veritas at this time in our development. David is a strong leader whose broad experience in small and large specialty pharmaceutical organizations uniquely qualifies him to lead and build our financial operations as we enter a transformative period in our Company,” said Dr. Lui Franciosi, CEO of Veritas. “Having previously managed financial planning, analysis and strategic growth initiatives for a variety of Exchange Listed companies, David has a thorough understanding of the exciting opportunities from which Veritas is poised to benefit.”

“The company is approaching a period of immense growth and opportunity. I look forward to working with the Veritas team to successfully execute on the goals ahead and to focus on driving significant shareholder return”, stated David Alexander.

About VERITAS Pharma Inc.

Veritas Pharma Inc. is an early stage pharmaceutical company developing innovative medicinal cannabis cultivars for specific disease conditions such as chronic pain, emesis (nausea/vomiting), and epilepsy. Using a ‘lean and mean’ approach to product development, the company aims to select candidate cultivars using classical pharmacology techniques and then immediately evaluate them in the clinic to maximize both product value and shareholder return. Veritas’s scientists are an inter-disciplinary team that consists of chemists, pharmacologists, anesthetists, and clinical pharmacologists. Their focus is to use their knowledge to streamline the development of cannabis based treatments to capture considerable market share. Also through its wholly owned subsidiary, Sechelt Organic Marijuana Corp., has applied to Health Canada for a medical marijuana production and distribution license under the Marihuana for Medical Purposes Regulations (the “MMPR“).

On behalf of the Board of Directors Veritas Pharma Inc.
“Dr. Lui Franciosi”
Dr. Lui Franciosi
Chief Executive Officer

Further information about the Company is available on our website at www.veritaspharmainc.com or under our profile on SEDAR at www.sedar.com and on the CSE website at www.thecse.com.

Investor and Public Relations Contact

Veritas Pharma Inc.
Dr. Lui Franciosi
Chief Executive Officer
Telephone: +1.778.968.6260
Email: [email protected]

The CSE has not reviewed, nor approved or disapproved the content of this press release.

The Veritas Newsletter

Enter your email to receive news alerts and updates from Veritas Pharma.

You have Successfully Subscribed!